With malignant ascites increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising demand for safer and more effective therapies. According to DelveInsight, the malignant ascites pipeline currently involves 5+ pharmaceutical and biotech companies developing 5+ therapeutic candidates. These therapies are at various stages of clinical and non-clinical development, highlighting strong innovation and commitment to addressing this significant public health challenge.
DelveInsight’s report, “Malignant Ascites Pipeline Insight 2025,” provides a comprehensive and strategic analysis of the R&D landscape, including clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving malignant ascites therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Malignant Ascites Drug Development
During the ERS Congress 2025 in September 2025, several biotechnology and pharmaceutical companies shared notable advancements in pulmonary and cardiopulmonary research:
-
In September 2025, Diagonal Therapeutics presented new preclinical data highlighting the potential of its lead clustering antibody, DIAG723, as a disease-modifying therapy for pulmonary arterial hypertension (PAH).
-
In September 2025, a study revealed that babies raised with dogs may have a reduced risk of developing childhood asthma.
-
In September 2025, Savara shared data from the Phase 3 IMPALA-2 trial of Molgramostim Inhalation Solution for patients with autoimmune pulmonary alveolar proteinosis (aPAP).
-
In September 2025, AllRock Bio, Inc. reported encouraging Phase 1 results for ROC-101, a first-in-class oral pan-ROCK inhibitor for cardiopulmonary and fibrotic diseases.
-
In September 2025, Gossamer Bio, Inc., in collaboration with Chiesi Group, announced five scientific presentations on seralutinib for PAH and PH-ILD.
-
In September 2025, Boehringer Ingelheim presented pooled analyses from the Phase III FIBRONEER™ program on nerandomilast, an investigational oral PDE4B inhibitor, showing a nominally significant reduction in mortality risk across IPF and PPF.
-
In September 2025, Kaia Health launched a pilot program of Kaia Breathe, a digital pulmonary rehabilitation solution for COPD patients, in partnership with MedImprove.
-
In September 2025, aTyr Pharma, Inc. shared additional findings from the Phase 3 EFZO-FIT™ study of efzofitimod in 268 patients with pulmonary sarcoidosis, a key form of interstitial lung disease.
Key Takeaways from the Malignant Ascites Pipeline Report
-
DelveInsight’s Malignant Ascites pipeline report highlights a dynamic landscape with 5+ active companies developing 5+ therapeutic candidates for the treatment of malignant ascites.
-
In December 2024, the U.S. FDA approved the Alfapump® system for managing recurrent or refractory ascites caused by liver cirrhosis. This implantable device automatically transfers excess fluid from the abdominal cavity to the bladder, reducing the need for frequent paracentesis and enhancing patients’ quality of life.
-
Leading companies in the malignant ascites space—including Clover Biopharmaceuticals, YZY Biopharma, Sorrento Therapeutics, Inc., Simcere, PharmaCyte Biotech, Linton Pharm, and others—are actively developing new therapies to improve treatment options.
-
Promising pipeline candidates under development include SCB-313 and several others.
Malignant Ascites Overview:
Ascites is the accumulation of fluid within the abdominal cavity surrounding internal organs. When caused by cancer, it is referred to as malignant ascites. This condition most frequently occurs in cancers of the colon or rectum, breasts, lungs, pancreas, liver, and in lymphoma. Approximately 50% of patients with malignant ascites also present with peritoneal carcinomatosis, while around 13% develop it due to widespread liver metastases that cause portal hypertension.
Malignant ascites can result from several mechanisms, including lymphatic obstruction caused by tumor growth, direct fluid secretion into the abdominal cavity by aggressive tumors, or the development of cirrhosis-like changes in patients with extensive liver involvement. The condition is generally associated with a poor prognosis, with median survival ranging from one to four months.
Download the Malignant Ascites sample report to know in detail about the Malignant Ascites treatment market
Malignant Ascites Pipeline Analysis
The Malignant Ascites pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Malignant Ascites Market.
-
Categorizes Malignant Ascites therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Malignant Ascites drugs under development based on:
-
Stage of development
-
Malignant Ascites Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Malignant Ascites Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Malignant Ascites Licensing agreements
-
Funding and investment activities supporting future Malignant Ascites market advancement.
-
Unlock key insights into emerging Malignant Ascites therapies and market strategies here: https://www.delveinsight.com/report-store/malignant-ascites-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Malignant Ascites Emerging Drugs
SCB-313 – Clover Biopharmaceuticals
Leveraging its Trimer-Tag™ technology platform, Clover Biopharmaceuticals has developed SCB-313, a covalently linked, native-like trimeric fusion protein. Its unique structure and function distinguish it from traditional dimeric antibody therapies and other native ligand-based approaches targeting the same pathway. SCB-313 is being investigated for the treatment of malignant ascites (MA), malignant pleural effusions (MPE), and peritoneal carcinomatosis (PC), addressing the high unmet need for therapies against intracavitary cancers. The therapy is currently in Phase I clinical trials for malignant ascites.
Malignant Ascites Pipeline Therapeutic Assessment
Malignant Ascites Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Malignant Ascites By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Malignant Ascites Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Malignant Ascites Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Malignant Ascites therapies and key Malignant Ascites companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Malignant Ascites Current Treatment Patterns
5. Malignant Ascites - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
5. Malignant Ascites Late-Stage Products (Phase-III)
7. Malignant Ascites Mid-Stage Products (Phase-II)
5. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
5. Inactive Products
11. Dormant Products
12. Malignant Ascites Discontinued Products
13. Malignant Ascites Product Profiles
15. Malignant Ascites Key Companies
15. Malignant Ascites Key Products
15. Dormant and Discontinued Products
17. Malignant Ascites Unmet Needs
15. Malignant Ascites Future Perspectives
19. Malignant Ascites Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Malignant Ascites pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/